MX361230B - Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas. - Google Patents

Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas.

Info

Publication number
MX361230B
MX361230B MX2013008606A MX2013008606A MX361230B MX 361230 B MX361230 B MX 361230B MX 2013008606 A MX2013008606 A MX 2013008606A MX 2013008606 A MX2013008606 A MX 2013008606A MX 361230 B MX361230 B MX 361230B
Authority
MX
Mexico
Prior art keywords
polypeptide
cyaa
immune responses
induce
therapeutic
Prior art date
Application number
MX2013008606A
Other languages
English (en)
Other versions
MX2013008606A (es
Inventor
Esquerré Michael
Momot Marie
Goubier Anne
Misseri Yolande
Original Assignee
Genticel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genticel filed Critical Genticel
Publication of MX2013008606A publication Critical patent/MX2013008606A/es
Publication of MX361230B publication Critical patent/MX361230B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición que comprende un primer grupo de epítopes y un segundo grupo de epítopes, para usarse en el tratamiento inmunoterapéutico de una primera condición patológica y profilaxis de una segunda condición patológica en un huésped mamífero, en donde los grupos de epítopes son de la proteína E6 o de la proteína E7 de un tipo de HPV oncogénico seleccionado del grupo que consiste en HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 Y HPV58, en donde el primer grupo de epítopes está contenido en un polipéptido y el segundo grupo de epítopes está contenido en el mismo polipéptido y dicho polipéptido es llevado por un vector o en donde el primer grupo de epítopes está contenido en un polipéptido diferente y dichos polipéptidos son llevados por el mismo vector o son llevados por vectores separados, y en donde el(los) vectores(es) es(son) una proteína CyaA, o un fragmento de la misma, en donde dicho primer grupo de epítopes no es suficiente para obtener profilaxis contra la segunda condición patológica, en donde el primer grupo de epítopes produce un respuesta inmune de células T contra el primer grupo de epítopes después de administrar dicha composición proporcionando así un tratamiento inmunoterapéutico contra dicha primera condición patológica asociada con dicho primer grupo de epítopes, y en donde, después de administrar dicha composición, el segundo grupo de epítopes produce una respuesta inmune de memoria de células T contra el segundo grupo de epítopes después de administrar dicha composicón, proporcionando así profilaxis contra dicha segunda condición patológica asociada con dicho segundo grupo de epítope.
MX2013008606A 2011-01-24 2012-01-24 Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas. MX361230B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305069A EP2478915A1 (en) 2011-01-24 2011-01-24 CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
PCT/EP2012/051027 WO2012101112A1 (en) 2011-01-24 2012-01-24 Cyaa-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses

Publications (2)

Publication Number Publication Date
MX2013008606A MX2013008606A (es) 2013-12-09
MX361230B true MX361230B (es) 2018-11-30

Family

ID=43971828

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008606A MX361230B (es) 2011-01-24 2012-01-24 Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas.

Country Status (12)

Country Link
US (1) US9902947B2 (es)
EP (2) EP2478915A1 (es)
JP (2) JP6014604B2 (es)
KR (1) KR101975610B1 (es)
CN (1) CN103476424A (es)
AU (1) AU2012210612B2 (es)
BR (1) BR112013018742A2 (es)
CA (1) CA2825470A1 (es)
ES (1) ES2748381T3 (es)
MX (1) MX361230B (es)
RU (1) RU2668795C2 (es)
WO (1) WO2012101112A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2689786A1 (en) * 2012-07-23 2014-01-29 Genticel HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
EP2690172A1 (en) 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3037103A1 (en) * 2014-12-23 2016-06-29 Genticel Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV
TWI806815B (zh) 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之ｇａｔａ３相關之腫瘤特異性新抗原
US10313363B2 (en) * 2015-11-24 2019-06-04 Bank Of America Corporation Proactive intrusion protection system
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334155T2 (de) 1992-04-21 2008-02-14 Institut Pasteur Rekombinante mutanten zur induktion spezifischer immunantworten
PT1188446E (pt) * 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
WO2005035557A2 (en) * 2003-10-14 2005-04-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease
EP1684801B1 (en) * 2003-11-21 2009-12-02 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
EP1576967B1 (en) * 2004-03-18 2007-09-12 Institut Pasteur Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof
RU2448729C2 (ru) * 2006-09-01 2012-04-27 Жантисель Композиции, вызывающие специфический ответ цитотоксических т-лимфоцитов, включающие лимфо-аблативное соединение и молекулу, содержащую антигенные последовательности и нацеленную на специализированные антиген-презентирующие клетки
EP1894941A1 (en) * 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
US20080254062A1 (en) * 2007-02-23 2008-10-16 The Penn State Research Foundation Use of an avirulent bordetella mutant as a live vaccine vector

Also Published As

Publication number Publication date
US9902947B2 (en) 2018-02-27
BR112013018742A2 (pt) 2017-11-14
KR101975610B1 (ko) 2019-05-07
WO2012101112A1 (en) 2012-08-02
JP2014506562A (ja) 2014-03-17
AU2012210612A1 (en) 2013-05-02
CA2825470A1 (en) 2012-08-02
RU2668795C2 (ru) 2018-10-02
JP2016208979A (ja) 2016-12-15
KR20140034147A (ko) 2014-03-19
ES2748381T3 (es) 2020-03-16
EP2478915A1 (en) 2012-07-25
AU2012210612B2 (en) 2016-07-14
JP6014604B2 (ja) 2016-10-26
EP2667890B1 (en) 2019-07-03
RU2013136148A (ru) 2015-03-10
MX2013008606A (es) 2013-12-09
EP2667890A1 (en) 2013-12-04
US20140037670A1 (en) 2014-02-06
CN103476424A (zh) 2013-12-25

Similar Documents

Publication Publication Date Title
MX2013008606A (es) Polipeptido (s) llevado por cyaa y uso para inducir respuestas inmunes tanto terapeuticas como profilacticas.
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
MX2014011066A (es) Moleculas de union novedosas con actividad antitumoral.
WO2014151960A3 (en) Methods for controlling t cell proliferation
NZ627078A (en) Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
MX2016000102A (es) Condicion de ayuno como tratamiento dietetico de la diabetes.
NZ628449A (en) Neisseria meningitidis compositions and methods thereof
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
MD20140104A2 (ro) Polipeptide care se leagă de CX3CR1
WO2015035250A3 (en) Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
WO2013188627A3 (en) Cationic lipid vaccine compositions and methods of use
WO2017096327A3 (en) Compositions and methods for reducing immune responses against chimeric antigen receptors
MX2016007903A (es) Metodos de elaboración de perfiles de epitopos de celulas t, elaboracion de composiciones de celulas t y tratamiento de enfermedades.
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
WO2012047267A3 (en) Polyvalent immunogen
WO2016023898A3 (en) Intracellular antigen binding
WO2014028668A3 (en) Stem cell enhancing therapeutics
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
WO2013001362A3 (en) Contiguous overlapping peptides for treatment of ragweed pollen allergy
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same

Legal Events

Date Code Title Description
FG Grant or registration